| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/23/2006 | WO2003075855A3 Antibodies against cancer antigen tmeff2 and uses thereof |
| 03/23/2006 | US20060064068 body fluids, such as urine, feces, menses; comprises a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent; applied to the skin by suitable delivery vehicles, such as absorbent articles or components thereof, sheet materials, pads, bandages, sponges, foam pads, pumps |
| 03/23/2006 | US20060063859 Transition metal-catalyzed synthesis of dendritic polymers |
| 03/23/2006 | US20060063839 Inhibitors of decrease in body temperature |
| 03/23/2006 | US20060063835 Composition based on triethyl citrate for the treatment of bacterial infections of the skin |
| 03/23/2006 | US20060063768 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa |
| 03/23/2006 | US20060063743 Peptide deformylase activated prodrugs |
| 03/23/2006 | US20060063714 Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides |
| 03/23/2006 | US20060063706 Bactericides with antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals; treating infection caused by methicillin-resistant Staphylococcus aureus |
| 03/23/2006 | US20060063699 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 03/23/2006 | US20060063237 Biologically pure bacterial cultures; alginate is produced in large amounts and with a certain determined content of mannuronate and guluronate residues; high yielding |
| 03/23/2006 | US20060062856 Controlled release galantamine composition |
| 03/23/2006 | US20060062842 Method of administering a compound to multi-drug resistant cells |
| 03/23/2006 | US20060062827 Nutritional supplement composition and method |
| 03/23/2006 | US20060062816 Improved absorption of mentrual fluid and decreased amounts on skin and hair; liquid pervious topsheet; the lotion contains a petroleum based hydrocarbon, lower molecular weight glycols or polyols and a fatty alcohol |
| 03/23/2006 | US20060062810 Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same |
| 03/23/2006 | US20060062809 Solid dispersions comprising two different polymer matrixes |
| 03/23/2006 | US20060062796 Polysaccharide-polypeptide conjugate |
| 03/23/2006 | US20060062795 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
| 03/23/2006 | US20060062793 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 03/23/2006 | US20060062789 Immunoglobulins; lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, immunodeficiency syndrome, asthma, allergic disorders, AIDS, and proliferative disorders such as leukemia |
| 03/23/2006 | US20060062782 Anti-IgE vaccines |
| 03/23/2006 | US20060062772 Polypeptide delivery system |
| 03/23/2006 | US20060062754 Polymeric modifiers and pharmaceutical compositions |
| 03/23/2006 | US20060062747 Use of sweetener acids for the microbiological stabilization of foodstuffs, cosmetic products, consumer goods and pharmaceutical productions |
| 03/23/2006 | DE10037121B4 Verwendung einer konzentrierten und stabilisierten antipyretischen Zusammensetzung für den tiermedizinischen Gebrauch als Zusatz zu Tiernahrung Using a concentrated and stabilized antipyretic composition for veterinary use as an additive to animal feed |
| 03/23/2006 | CA2584553A1 External agent for treatment of skin ulcer |
| 03/23/2006 | CA2581076A1 D-methionine formulation with improved biopharmaceutical properties |
| 03/23/2006 | CA2581020A1 Method and composition for preventing or treating diarrhea |
| 03/23/2006 | CA2580659A1 Corticosteroid having low systemic absorption |
| 03/23/2006 | CA2580537A1 Compositions and their uses for lysosomal enzyme deficiencies |
| 03/23/2006 | CA2580370A1 Reducing er stress in the treatment of obesity and diabetes |
| 03/23/2006 | CA2580202A1 Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| 03/23/2006 | CA2579900A1 Cancerous disease modifying antibodies |
| 03/23/2006 | CA2579725A1 Highly-aqueous non-respirable aerosols containing biologically-active ingredients method of making and device therefor |
| 03/23/2006 | CA2578248A1 Multiple sclerosis treatment |
| 03/23/2006 | CA2578131A1 Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
| 03/23/2006 | CA2577336A1 Permucosal composition and method of improving permucosal absorption |
| 03/23/2006 | CA2570450A1 Pharmaceutically elegant, topical anhydrous aerosol foam |
| 03/23/2006 | CA2544776A1 Polyethylene oxide-based films and drug delivery systems made therefrom |
| 03/22/2006 | EP1637598A1 Cd47 partal peptdie and anti-shps-1 monoclonal antibody |
| 03/22/2006 | EP1637593A1 Process for the inactivation of enveloped viruses |
| 03/22/2006 | EP1637547A1 Process for the preparation of a polymeric hydrogel based on a highly purified polyvinylalcohol and uses thereof |
| 03/22/2006 | EP1637170A1 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 03/22/2006 | EP1637167A2 New injectable formulations containing progesterone |
| 03/22/2006 | EP1637166A2 Virus-like particles for the induction of autoantibodies |
| 03/22/2006 | EP1637165A1 Medicinal cooling emulsions |
| 03/22/2006 | EP1637164A2 Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 03/22/2006 | EP1637163A1 Indicator of therapeutic compliance |
| 03/22/2006 | EP1637160A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 03/22/2006 | EP1637158A2 Capsular polysaccharide immunomodulator |
| 03/22/2006 | EP1637154A2 High molecular weight medicine-containing preparation in powder form for administration through mucosa |
| 03/22/2006 | EP1637144A1 Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
| 03/22/2006 | EP1637142A2 Stable solid formulation of enalapril salt and process for preparation thereof |
| 03/22/2006 | EP1637132A1 External preparation for athlete´s foot treatment |
| 03/22/2006 | EP1637128A2 Use of simple amino acids to form porous particles |
| 03/22/2006 | EP1637127A2 Generation of therapeutic microfoam |
| 03/22/2006 | EP1637126A2 Methods for treating inflammation of the eye |
| 03/22/2006 | EP1636334A2 Recombinant anti-cd30 antibodies and uses thereof |
| 03/22/2006 | EP1636263A2 Pegylated soluble gp130-dimers useful as a medicament |
| 03/22/2006 | EP1636250A2 Self-assembling peptides incorporating modifications and methods of use thereof |
| 03/22/2006 | EP1635879A2 Lectin conjugates |
| 03/22/2006 | EP1635875A2 In-situ gelling drug delivery system |
| 03/22/2006 | EP1635874A1 Compositions for oral administration of campothecin and its analogs |
| 03/22/2006 | EP1635873A2 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 03/22/2006 | EP1635868A1 Methods for treating cancer using an immunotoxin |
| 03/22/2006 | EP1635858A2 Targeted delivery to legumain-expressing cells |
| 03/22/2006 | EP1635854A2 Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| 03/22/2006 | EP1635852A1 Nail restructuring compositions for topical application |
| 03/22/2006 | EP1635797A1 Hydrophilic adhesive compositions for delivery of herbal medicines |
| 03/22/2006 | EP1635796A1 Fast dissolving orally consumable films containing sucralose as a sweetener |
| 03/22/2006 | EP1635792A1 Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| 03/22/2006 | EP1635770A2 Antifungal nail coat and method of use |
| 03/22/2006 | EP1635766A2 Lactoferrin as an adjuvant in cancer vaccines |
| 03/22/2006 | EP1635764A2 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof |
| 03/22/2006 | EP1597278A4 Polyethylene glycol modified interferon compositions and methods of use thereof |
| 03/22/2006 | EP1587945A4 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 03/22/2006 | EP1495103A4 Targeted controlled delivery compositions activated by changes in ph or salt concentration |
| 03/22/2006 | EP1461436A4 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 03/22/2006 | EP1458377B1 Tegaserod pharmaceutical compositions |
| 03/22/2006 | EP1458246A4 Process for preparing chewing gum containing a nutritional supplement |
| 03/22/2006 | EP1437975A4 Optically-absorbing nanoparticles for enhanced tissue repair |
| 03/22/2006 | EP1411896B1 Surfactant compounds and uses thereof |
| 03/22/2006 | EP1404301A4 Stable controlled release pharmaceutical compositions containing pravastatin |
| 03/22/2006 | EP1346021B1 Prevention of preservative uptake into ophthalmic lenses |
| 03/22/2006 | EP1328253B1 Administration of a thiol-based chemoprotectant compound |
| 03/22/2006 | EP1322287B1 Microparticles for delivery of the heterologous nucleic acids |
| 03/22/2006 | EP1311522B1 New immunoeffector compounds |
| 03/22/2006 | EP1278495A4 Topical compositions containing prostaglandin e 1? |
| 03/22/2006 | EP1269845B1 Bacterial growth regulators or inhibitors with the use of 1,5-d-anhydrofructose |
| 03/22/2006 | EP1207867B1 Oral pharmaceutical forms of administration with a delayed action with tramadol |
| 03/22/2006 | EP1194121B1 Steroid solution aerosol products with enhanced chemical stability |
| 03/22/2006 | EP1093818B1 Powdery preparation for mucosal administration containing polymeric medicine |
| 03/22/2006 | EP1017403B1 Use of zinc hyaluronate against peptic ulcer |
| 03/22/2006 | EP1005326A4 Method for producing liposomes with increased percent of compound encapsulated |
| 03/22/2006 | EP0972520B9 Freeze-dried composition of bone morphogenetic protein human mp52 |
| 03/22/2006 | EP0789564B1 Polynucleotide compositions |
| 03/22/2006 | CN1750849A 组织再生 Tissue Regeneration |
| 03/22/2006 | CN1750839A Administration of capsaicinoids |
| 03/22/2006 | CN1750816A Composition comprising cysteamine for improving immunity of animals |